Biocytogen (HKEX: 02315), a global biotech company dedicated to discovering and developing novel antibody therapeutics, ...

Oxford, UK and San Jose, California, 9 January 2024 - (OBT), a clinical stage oncology company with a pipeline of ...

Vir Biotechnology's recent share price rally is driven by their promising cancer program. Having shot to over a $1.5B market ...

Funding will propel Leyden Labs’ non-vaccine intranasal antibody programs to safeguard people from respiratory viruses. The ...

Agreement supports the research and development of up to five novel therapeutic antibodies identified through Alchemab's antibody discovery platform. CAMBRIDGE, England, Jan. 9, 2025 /PRNewswire/ ...

The trading of TCE (T Cell Engager) bispecific antibodies remains hot, and multinational pharmaceutical companies (MNCs) are still placing orders frantically.Recently ...

Respiratory illnesses are on the rise across San Antonio, Bexar County and Texas. Doctor Jason Bowling, a professor and infectious diseases specialist at UT Health San Antonio and the Chief ...

What's on the horizon for the life sciences industry? Robin Johnson, PharmD, Gene Therapy Submissions Lead, inSeption Group What unique challenges do gene therapy submissions face compared to ...

RQ Bio welcomes positive CHMP opinion on Kavigale for prevention of COVID-19 in immunocompromised individualsKavigale (sipavibart; AZD3152) is a ...

Johnson & Johnson has won Food and Drug Administration priority review for its application seeking approval of nipocalimab in certain patients with generalized myasthenia gravis.

The application is supported by data from the randomized, double-blind, placebo-controlled phase 3 Vivacity-MG3 study.

A novel tool known as the Florey Dementia Index (FDI) predicted onset age of mild cognitive impairment or Alzheimer's disease ...